Xia Chen,Xiaoming Zhang,Xiangji Lu,Meng Ren,Rina Su,Weishi Gao,Yanwei Gao. Enhancing the treatment effects of tumor cell purified autogenous heat shock protein 70-peptide complexes on HER-3-overexpressing breast cancer*. Oncol Transl Med, 2021, 7: 165-171.
Enhancing the treatment effects of tumor cell purified autogenous heat shock protein 70-peptide complexes on HER-3-overexpressing breast cancer*
Received:February 24, 2021  Revised:July 29, 2021
View Full Text  View/Add Comment  Download reader
KeyWord:heat shock protein 70 peptide complexes (HSP70-PCs); HER-3 protein; recombinant protein; dendritic cells (DCs); cellular immunotherapy
Author NameAffiliationPostcode
Xia Chen Inner Mongolia Red Cross Blood Center, Hohhot, Inner Mongolia 010010, China 010010
Xiaoming Zhang Inner Mongolia People’s Hospital, Hohhot, Inner Mongolia 010017, China 
Xiangji Lu Inner Mongolia Armed Police Hospital, Hohhot, Inner Mongolia 010010, China 
Meng Ren Inner Mongolia People’s Hospital, Hohhot, Inner Mongolia 010017, China 
Rina Su Inner Mongolia People’s Hospital, Hohhot, Inner Mongolia 010017, China 
Weishi Gao Inner Mongolia People’s Hospital, Hohhot, Inner Mongolia 010017, China * 
Yanwei Gao Inner Mongolia People’s Hospital, Hohhot, Inner Mongolia 010017, China * 010017
Hits: 360
Download times: 441
Abstract:
      Objective The aim of this study was to enhance the treatment effect of tumor purified autogenous heat shock protein 70-peptide complexes (HSP70-PCs) on HER-3-overexpressing breast cancer. Methods In this study, we first studied the expression of HER-3 in breast cancer tissues and its relationship with patient characteristics. We then purified HSP70-PCs from primary breast cancer cells with different HER-2 and HER-3 expression profiles and determined the cytotoxicity of autogenous dendritic cells (DCs) and CD8+ T cells induced by these complexes. Third, recombinant human HSP70-HER-3 protein complexes were used to inhibit the autogenous HSP70-PCs purified from HER-3–overexpressing breast cancer cells, and the resulting immunological response was examined. Results The results show that HSP70-PCs can be combined with recombinant HSP70-HER-3 protein complexes to induce stronger immunological responses than autogenous HSP70-PCs alone and that these treatments induce autogenous CD8+ T cell killing of HER-3-positive breast cancer cells. Conclusion These findings provide a new direction for HSP70-DC-based immunotherapy for patients with HER-3-overexpressing breast cancer.
Close